JointHealth™ express July 27, 2016
Correction to July 12’s JointHealth™ insight
Correction for apremilast (Otezla®) listing in the Ontario drug formulary
A reference in the July 12, 2016 online publication of JointHealth™ insight referred incorrectly to the listing of apremilast (Otezla®) for the treatment of psoriatic arthritis in the Ontario drug formulary as “declined." The medication should be listed as “under review” as it is still under consideration for reimbursement.
Click here to see the updated Report Card.
We want to hear from you. If you have been affected by the delayed review of apremilast (Otezla®), please contact us at feedback@jointhealth.org.
Correction to July 12’s JointHealth™ insight
Correction for apremilast (Otezla®) listing in the Ontario drug formulary
A reference in the July 12, 2016 online publication of JointHealth™ insight referred incorrectly to the listing of apremilast (Otezla®) for the treatment of psoriatic arthritis in the Ontario drug formulary as “declined." The medication should be listed as “under review” as it is still under consideration for reimbursement.
Click here to see the updated Report Card.
We want to hear from you. If you have been affected by the delayed review of apremilast (Otezla®), please contact us at feedback@jointhealth.org.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.